SOMERSET, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell…
GERMANTOWN, Md., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on…
Additional real-world studies show sustained HAE attack rate reduction after initiating ORLADEYO, regardless of C1-INH status, and patient preference for…
Completed OAS challenge study meets both primary and secondary endpointsDemonstrates rapid resolution of allergen-related symptoms beginning two minutes after administration…
New patient-reported outcome data from INTEGUMENT-1 and -2 demonstrate that ZORYVE cream 0.15% rapidly decreased the impact of atopic dermatitis…
Publication shows that OGM can resolve translocation partners involving MYC in multiple myeloma (MM) more effectively than current methodsThe release…
New funding will support strategic expansion of PeopleOne Health, improving access to preventive care and treatment to keep people healthier…
– Combination of ziftomenib and imatinib shows robust and durable antitumor activity in imatinib-sensitive (1L) and imatinib-resistant (2L/3L) GIST models…
PRINCETON, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Soligenix, Inc. (Nasdaq: SNGX) (“Soligenix” or the “Company”) a late-stage biopharmaceutical company…
- Continued, progressive improvement in motor function and achievement of motor milestones at 12-months post-treatment represents an important and statistically…